---
title: "Guilin Sanjin: BC006 monoclonal antibody injection new indication approved for clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238717044.md"
description: "According to the Zhitong Finance APP, Guilin Sanjin announced that its holding subsidiary, Baochuan Biopharmaceutical Technology (Shanghai) Co., Ltd. (referred to as \"Baochuan Biopharma\"), has received the clinical trial approval for BC006 monoclonal antibody injection issued by the National Medical Products Administration, allowing the commencement of clinical trials for the indication of idiopathic pulmonary fibrosis"
datetime: "2025-05-05T07:59:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238717044.md)
  - [en](https://longbridge.com/en/news/238717044.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238717044.md)
generator: "portal-rs"
---

# Guilin Sanjin: BC006 monoclonal antibody injection new indication approved for clinical trials

According to the Zhitong Finance APP, Guilin Sanjin (002275.SZ) announced that its controlling subsidiary, Baochuan Biopharmaceutical Technology (Shanghai) Co., Ltd. (referred to as "Baochuan Biopharmaceutical"), has received the clinical trial approval for BC006 monoclonal antibody injection issued by the National Medical Products Administration, allowing the clinical trial for the indication of idiopathic pulmonary fibrosis to proceed

### Related Stocks

- [002275.CN](https://longbridge.com/en/quote/002275.CN.md)

## Related News & Research

- [The Outlook for a Smaller Ghana Cocoa Crop Supports Prices](https://longbridge.com/en/news/296516744.md)
- [ANALYSIS-War-hit European markets are far from down and out](https://longbridge.com/en/news/296565595.md)
- [TECHNICALS-CBOT wheat may retest support at $6.60-3/4](https://longbridge.com/en/news/296316121.md)
- [EXPLAINER-Why a super El Niño leaves tropical commodities acutely exposed](https://longbridge.com/en/news/296197492.md)
- [Alpha Entrepreneurial Partners Investment TGV takes 3.03% stake in q.beyond voting rights](https://longbridge.com/en/news/296450706.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**